Drug Therapy
Large study will evaluate n-3 polyunsaturated fatty acids and rosuvastatin
Published in Heart Disease Weekly, November 7th, 2004
According to the report from Italy, "The GISSI Heart Failure project is a large-scale, randomized, double-blind study designed to investigate the effects of n-3 polyunsaturated fatty acids and rosuvastatin on mortality and morbidity in patients with symptomatic heart failure."
L. Tavazzi and colleagues of the Policlinico San Matteo in Pavia explained, "Patients with New York Heart Association classes II to IV heart failure, already receiving optimized recommended therapy, will be recruited in a nationwide network of more than 300 cardiology and internal medicine...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
Source: Heart Disease Weekly (2004-11-07)
More Articles from Heart Disease Weekly
- Cardiac Devices
Biventricular ICDs offer survival benefit compared to biventricular pacing alone - Cardiac Devices
Thin filament is key modulator of contractile performance in failing human heart - Heart Failure
The burden of heart failure is greater in ethnic minority populations - Ventricular Fibrillation
Radiofrequency ablation in children with Wolff-Parkinson-White syndrome studied - Abdominal Aortic Aneurysm
Estrogen protects male rats from aneurysm - Abdominal Aortic Aneurysm
FDA approves medical device to treat AAA - More from this issue of Heart Disease Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
